Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epigenetic Modulation with Azacitidine and Lenalidomide in Relapsed/Refractory Lymphoma
NCT01121757Phase 2Terminated
- Sponsor
- Duke University
- Start
- Apr 2010
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine and lenalidomide in follicular lymphoma (FL) and marginal zone lymphoma (MZL) (2 arms), sponsored by Duke University. Primary endpoints: Response Predicted by Molecular Signatures Compared to True Response at 1 year and Overall Response at 4 months. Started Apr 2010; status: terminated.
02
Drugs
azacitidinelenalidomide
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT01121757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121757.